ScreenPoint Medical Unveils New FDA Approval to Enhance Breast Cancer Detection at RSNA

Introduction

The world of medical technology is constantly evolving, and at the 110th Annual Meeting of the Radiological Society of North America (RSNA) held from December 1 to 4, 2024, a groundbreaking announcement was made. ScreenPoint Medical introduced FDA-approved enhancements to its Breast AI system, Transpara. This innovation aims to improve breast cancer detection while assisting radiologists in their efforts to provide efficient and accurate diagnoses.

Overview of Transpara

Transpara is recognized as one of the leading breast cancer detection algorithms globally, backed by extensive clinical validation. During the recent RSNA conference, the company showcased the latest version, Transpara 2.1, which incorporates advanced features such as breast density assessment options and the ability to compare results over time. With its redesigned algorithm, which includes comprehensive training from global experts, Transpara 2.1 provides radiologists with a second pair of eyes, making the detection of breast cancer more reliable and timely.

Key Features of Transpara 2.1

One of the standout features of Transpara 2.1 is its ability to analyze and compare imaging data over a period of up to six years with up to three prior studies. This robust temporal comparison functionality is pioneering in the industry. Professor Nico Karssemeijer, PhD, Chief Scientific Officer of ScreenPoint Medical, highlighted the significance of this capability, stating that it effectively characterizes findings by considering tissue changes and significantly enhances the algorithm's performance.

Moreover, Transpara maintains its strong presence in the market as it is both CE marked and FDA approved, ensuring that healthcare facilities using this technology can have confidence in its efficacy and safety. Additionally, Transpara's enhancements are expected to streamline workflows and improve overall clinical outcomes, making it an essential tool for radiologists worldwide.

Clinical Implications and Studies

Apart from the technical advancements, Transpara's implementation has been the subject of various clinical studies presented during RSNA 2024. For instance, a prospective study titled "Putting It In Perspective AI Triage Streamlining Screening Mammogram Turnaround Time (Tat) Amid Staff Shortages" evaluated how AI software can prioritize mammogram interpretations, thus reducing turnaround times dramatically. Results revealed significant workflow benefits attributed to prioritizing readings using the Transpara assessment.

Another study, examining the use of Transpara as an independent third reader in Germany's mammography screening program, showcased its ability to increase cancer detection rates, especially for invasive cancer types, further proving its value in enhancing diagnostic accuracy.

Moreover, researchers presented findings on the performance of the AI system with dense breast cases, asserting that Transpara's marked studies demonstrated strong predictive value for cancer, proving effective for both dense and non-dense breast tissue.

Conclusion

With over 35 peer-reviewed publications, Transpara stands out as the only breast AI algorithm extensively evaluated in real-world screening populations. Notable research from institutions like UCLA and the Norwegian Cancer Registry confirms that Transpara can identify interval cancers up to 45% sooner while simultaneously reducing the radiologist's workload and optimizing workflow efficiency.

ScreenPoint Medical continues to translate cutting-edge research in machine learning into accessible technology for radiologists. With advancements like Transpara, the company aims to enhance the breast cancer screening process, providing the confidence and support radiologists need to deliver exceptional care to their patients. Further details and published evidence can be found on ScreenPoint Medical's official website.